TTOO Historical Financial Ratios
TTOO Stock | USD 0.37 0.08 17.78% |
T2 Biosystms is promptly reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 0.0, Stock Based Compensation To Revenue of 0.57, Capex To Depreciation of 0.21 or Ev To Sales of 6.63 will help investors to properly organize and evaluate T2 Biosystms financial condition quickly.
TTOO |
About TTOO Financial Ratios Analysis
T2 BiosystmsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate T2 Biosystms investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on TTOO financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across T2 Biosystms history.
T2 Biosystms Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing T2 Biosystms stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on T2 Biosystms sales, a figure that is much harder to manipulate than other T2 Biosystms multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from T2 Biosystms' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.At this time, T2 Biosystms' Days Sales Outstanding is very stable compared to the past year. As of the 14th of December 2024, Days Of Inventory On Hand is likely to grow to 120.22, while Price To Sales Ratio is likely to drop 2.16.
2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 7.31 | 16.31 | 10.06 | 14.63 | Days Of Inventory On Hand | 68.92 | 75.09 | 114.49 | 120.22 |
T2 Biosystms fundamentals Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 6.39 | 8.3 | 2.92 | 0.32 | 2.28 | 2.16 | |
Ptb Ratio | (1.57) | 17.24 | (6.35) | (0.18) | (0.58) | (0.56) | |
Days Sales Outstanding | 123.71 | 102.65 | 66.79 | 35.4 | 72.06 | 131.22 | |
Book Value Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
Free Cash Flow Yield | (0.87) | (0.29) | (0.48) | (7.04) | (2.95) | (2.8) | |
Operating Cash Flow Per Share | (5.0K) | (1.8K) | (1.2K) | (992.67) | (18.44) | (19.37) | |
Stock Based Compensation To Revenue | 0.65 | 0.22 | 0.25 | 0.29 | 0.6 | 0.57 | |
Capex To Depreciation | 0.24 | 0.21 | 0.25 | 0.18 | 0.15 | 0.22 | |
Pb Ratio | (1.57) | 17.24 | (6.35) | (0.18) | (0.58) | (0.56) | |
Ev To Sales | 10.44 | 10.45 | 4.17 | 2.52 | 6.98 | 6.63 | |
Free Cash Flow Per Share | (5.1K) | (1.8K) | (1.2K) | (999.31) | (18.52) | (19.44) | |
Roic | (6.26) | (0.81) | (1.34) | (5.12) | (3.34) | (3.51) | |
Inventory Turnover | 4.66 | 5.85 | 5.3 | 4.86 | 3.19 | 3.03 | |
Net Income Per Share | (6.9K) | (2.0K) | (1.7K) | (1.2K) | (19.19) | (20.15) | |
Days Of Inventory On Hand | 78.37 | 62.37 | 68.92 | 75.09 | 114.49 | 120.22 | |
Payables Turnover | 4.47 | 10.34 | 7.31 | 16.31 | 10.06 | 14.63 | |
Research And Ddevelopement To Revenue | 1.96 | 0.93 | 0.78 | 1.16 | 1.97 | 1.87 | |
Capex To Revenue | 0.0913 | 0.0443 | 0.0164 | 0.0152 | 0.0267 | 0.0254 | |
Cash Per Share | 1.2K | 1.7K | 1.0K | 202.52 | 6.01 | 5.71 | |
Pocfratio | (1.17) | (3.48) | (2.11) | (0.14) | (0.34) | (0.36) | |
Interest Coverage | (7.08) | (7.51) | (6.52) | (9.12) | (9.3) | (9.76) | |
Capex To Operating Cash Flow | (0.0168) | (0.0186) | (0.0118) | (0.006696) | (0.003989) | (0.004188) | |
Pfcf Ratio | (1.15) | (3.42) | (2.08) | (0.14) | (0.34) | (0.36) | |
Days Payables Outstanding | 81.72 | 35.3 | 49.93 | 22.38 | 36.28 | 57.38 | |
Roe | 1.86 | (5.64) | 4.15 | 1.59 | 1.79 | 1.88 | |
Ev To Operating Cash Flow | (1.92) | (4.38) | (3.01) | (1.11) | (1.04) | (1.1) | |
Pe Ratio | (0.84) | (3.06) | (1.53) | (0.11) | (0.33) | (0.34) | |
Return On Tangible Assets | (2.22) | (0.62) | (0.88) | (1.84) | (1.44) | (1.51) | |
Ev To Free Cash Flow | (1.89) | (4.3) | (2.97) | (1.1) | (1.04) | (1.09) | |
Earnings Yield | (1.19) | (0.33) | (0.65) | (8.75) | (3.06) | (2.9) | |
Net Debt To E B I T D A | (0.7) | (1.01) | (0.85) | (0.89) | (0.77) | (0.73) | |
Current Ratio | 0.31 | 5.47 | 3.8 | 1.85 | 0.45 | 0.43 | |
Tangible Book Value Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
Receivables Turnover | 2.95 | 3.56 | 5.47 | 10.31 | 5.07 | 5.11 | |
Graham Number | 24.1K | 4.1K | 3.9K | 4.7K | 68.1 | 64.69 | |
Shareholders Equity Per Share | (3.7K) | 359.6 | (406.11) | (783.66) | (10.74) | (11.28) | |
Debt To Equity | (1.26) | 5.18 | (3.7) | (1.28) | (1.53) | (1.45) | |
Capex Per Share | 83.61 | 33.13 | 14.48 | 6.65 | 0.0736 | 0.0699 |
Pair Trading with T2 Biosystms
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if T2 Biosystms position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in T2 Biosystms will appreciate offsetting losses from the drop in the long position's value.Moving together with TTOO Stock
Moving against TTOO Stock
0.92 | BMY | Bristol Myers Squibb | PairCorr |
0.88 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
0.73 | ESPR | Esperion Therapeutics | PairCorr |
0.52 | DYAI | Dyadic International | PairCorr |
0.37 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to T2 Biosystms could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace T2 Biosystms when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back T2 Biosystms - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling T2 Biosystms to buy it.
The correlation of T2 Biosystms is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as T2 Biosystms moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if T2 Biosystms moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for T2 Biosystms can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.